AstraZeneca confirmed on June 1, 2026 that its oral GLP-1 drug elecoglipron (AZD5004) hit the primary endpoints in two Phase 2b trials — VISTA in obesity and SOLSTICE in type 2 diabetes — and will present the full data at the American Diabetes Association 2026 Scientific Sessions on June 8. The catch: AstraZeneca is holding back the actual weight-loss numbers until that presentation. For anyone tracking the oral GLP-1 race behind orforglipron, this is the next contender to watch.
The short version: another once-daily pill is advancing, but it changes nothing you can buy today. Here is the full picture.
Research-context information only. Peptides discussed below are research compounds. Protocols, doses, and reactions reported come from published research and self-reported community sources. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.
What AstraZeneca Just Announced
Elecoglipron — also labeled AZD5004 or ECC5004 — is an investigational oral, small-molecule GLP-1 receptor agonist. Like orforglipron, it is not a peptide: it is a pill designed for once-daily dosing with no food- or water-timing restrictions, which is the practical limitation that hobbled oral semaglutide.
Two Phase 2b trials read out as positive:
- VISTA — a randomized, double-blind, placebo-controlled study in adults living with obesity or overweight with a comorbidity. Reported as meeting its primary endpoint.
- SOLSTICE — a randomized, double-blind, placebo-controlled and open-label active-comparator study in adults with type 2 diabetes. Also reported as meeting its primary endpoint.
AstraZeneca has not disclosed the magnitude of weight loss or A1c reduction. Those numbers come out across two ADA sessions: an Eccogene poster on Sunday, June 7 (Poster Hall #2844-LB, 12:30 p.m. CT) and an AstraZeneca symposium on Monday, June 8 (Great Hall A, 3:15 p.m. CT).
The drug traces back to Eccogene, which licensed it globally to AstraZeneca in November 2023 while keeping co-development and co-commercialization rights in Greater China. An earlier 16-week Phase 1b trial in 45 Chinese participants reported "clinically meaningful" weight reduction and an A1c drop in the diabetes cohort, with mostly mild-to-moderate gastrointestinal side effects and no treatment-related discontinuations — the standard GLP-1 tolerability signature.
What This Means for You
Practically, elecoglipron changes nothing you can act on right now. It is investigational, not approved, and not sold anywhere. The honest read is that it is one more entrant in a crowded oral GLP-1 pipeline — interesting for the long game, irrelevant to a purchase decision this month.
Here is where the current oral and injectable options actually stand:
| Compound | Status | Route | Reported weight loss |
|---|---|---|---|
| Elecoglipron (AZD5004) | Phase 2b | Daily pill | Not yet disclosed (ADA June 8) |
| Orforglipron | FDA approved (Apr 2026) | Daily pill | ~12% at 72 weeks |
| Oral semaglutide | Approved | Daily pill (food-timed) | Lower than injectable |
| Injectable semaglutide | Approved | Weekly injection | ~15% at 68 weeks |
| Injectable tirzepatide | Approved | Weekly injection | ~20-22% at 72 weeks |
| Retatrutide | Phase 3 (TRIUMPH-1 positive) | Weekly injection | Up to ~28% at 80 weeks |
Two takeaways. First, oral GLP-1s win on convenience, not on efficacy — every injectable in the table outperforms the pills on weight loss to date. Second, if your priority is maximum results, the injectable peptides still lead, with retatrutide at the top after its TRIUMPH-1 Phase 3 readout.
For buyers sourcing quality-tested GLP-1 peptides today, here are the current options:
